inPractice® - Non–Genotype 1 HCV/HIV Coinfection

Hepatitis C Management in Special Populations

Author: Mark S. Sulkowski, MD (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 8/17/18 (What's New)

Summary

AASLD/IDSA guidance panel recommends DAA regimens as preferred therapy for genotype 2-6 HCV infection in patients with HCV/HIV coinfection (Management Guidelines)^{[AASLD-IDSA HCV]}
EASL guidance panel recommends DAA regimens for genotype 2-6 HCV infection in patients with HCV/HIV coinfection (Management Guidelines)^{[EASL HCV]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C, Hepatitis C-Special Populations, Hepatitis C-Sustained Virologic Response, Hepatitis C-Treatment